The first gene therapy for hemophilia B, Hemgenix, will have a list price of $3.5 million per use. This sets a new record for the most expensive single-use gene therapy in the U.S. In spite of the very high price tag, the budgetary impact of the product for most payers will be comparatively small.
Subscribe to:
Post Comments (Atom)
< + > Ditch the Security Snapshots. Why TripleKey Says Point-in-Time Audits Must End.
Security in healthcare is tough. Threats keep increasing rapidly. The attack surface is expanding. It feels incredibly overwhelming today. A...
No comments:
Post a Comment